Doubts raised about Provenge's efficacy; Breast cancer vaccine triggers an immune response;

> Activist Marie Huber has raised doubts about the efficacy of Provenge, the first therapeutic cancer vaccine, in prostate cancer. Article

> New hepatitis C antibodies could point to vaccine targets. Press release

> Generex Biotechnology subsidiary Antigen Express' AE37 breast cancer vaccine triggers an immune response, which could back up its ability to reduce recurrence. Press release

> Cancer stem cells could be used as an approach to cancer vaccination. Press release

> Astellas Pharma and Vical have finalized the design of a pivotal Phase III trial of TransVax, a therapeutic CMV vaccine for transplant recipients; the trial is planned for the second half of the year. Press release

> Whooping cough vaccine efficacy seems to wear off in pre-teens. Abstract | Article

> Merck ($MRK) has published efficacy and safety data for its shingles vaccine Zostavax in adults aged 50 to 59. Press release

> Bacillus Calmette-Guérin, a vaccine against tuberculosis, is a standard of care for some forms of bladder cancer; in Phase III trials, the Connaught strain of bacillus Calmette-Guérin is more effective than the Tice strain. Press release

> Inovio Pharmaceuticals ($INO) has received a U.S. Department of Defense SBIR grant to develop needle-free DNA vaccines against viruses with bioterrorism potential, including hanta, puumala, arenavirus and pandemic influenza. Press release

And Finally… Chile stops using mercury in vaccines. Press release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.